Italy Antibody Drug Conjugates Market Size & Outlook

The antibody drug conjugates market in Italy is expected to reach a projected revenue of US$ 758.8 million by 2030. A compound annual growth rate of 19.4% is expected of Italy antibody drug conjugates market from 2022 to 2030.
Revenue, 2021 (US$M)
$154.3
Forecast, 2030 (US$M)
$758.8
CAGR, 2022 - 2030
19.4%
Report Coverage
Italy

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Italy antibody drug conjugates market, 2018-2030 (US$M)

Italy antibody drug conjugates market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Italy antibody drug conjugates market highlights

  • The Italy antibody drug conjugates market generated a revenue of USD 154.3 million in 2021 and is expected to reach USD 758.8 million by 2030.
  • The Italy market is expected to grow at a CAGR of 19.4% from 2022 to 2030.
  • In terms of segment, breast cancer was the largest revenue generating application in 2021.
  • Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.


Antibody drug conjugates market data book summary

Market revenue in 2021USD 154.3 million
Market revenue in 2030USD 758.8 million
Growth rate19.4% (CAGR from 2021 to 2030)
Largest segmentBreast cancer
Fastest growing segmentBlood Cancer
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationBlood Cancer, Breast Cancer
Key market players worldwidePfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA


Other key industry trends

  • In terms of revenue, Italy accounted for 2.7% of the global antibody drug conjugates market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
  • Italy is the fastest growing regional market in Europe and is projected to reach USD 758.8 million by 2030.

Breast cancer was the largest segment with a revenue share of 70.64% in 2021. Horizon Databook has segmented the Italy antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.


Bureaucratic hurdles in the approval of new drugs and the high cost of new drugs are often cited by the Italian Association for Medical Oncology, even though the country’s National Health Service is known for reimbursing ADC drugs such as Kadcyla.

Kadcyla, Adectris, Besponsa, and Mylotarg are some of the ADCs currently available on the market. The approval of new ADCs, coupled with the growing incidence of various target indications, is expected to drive the market during the forecast period.

For instance, in May 2021, Mediterranea Theranostic Srl, an Italian biopharmaceutical firm, licensed its anti-Trop2 (tumor associated calcium signal transducer) to Lego Chem for ADC use through a contract after joint research over two years.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antibody Drug Conjugates Market Companies

Name Profile # Employees HQ Website
ADC Therapeutics SA View profile 274 Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 https://www.adctherapeutics.com
GlaxoSmithKline Consumer Healthcare (GSK CH India) View profile 1001-5000 Gurgaon, Haryana, India, Asia https://india-consumer.gsk.com/
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Daiichi Sankyo Co Ltd View profile 17435 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 https://www.daiichisankyo.com
Takeda Pharmaceutical Co Ltd View profile 49095 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 https://www.takeda.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com

Italy antibody drug conjugates market size, by application, 2018-2030 (US$M)

Italy Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)

Italy antibody drug conjugates market size, by application, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online